Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Up 38.0% in January

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totaling 52,250 shares, a growth of 38.0% from the December 31st total of 37,856 shares. Currently, 2.7% of the shares of the company are short sold. Based on an average trading volume of 41,827 shares, the days-to-cover ratio is currently 1.2 days. Based on an average trading volume of 41,827 shares, the days-to-cover ratio is currently 1.2 days. Currently, 2.7% of the shares of the company are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Alaunos Therapeutics in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Alaunos Therapeutics Price Performance

Alaunos Therapeutics stock opened at $2.75 on Tuesday. Alaunos Therapeutics has a 12 month low of $1.31 and a 12 month high of $6.20. The business has a 50 day simple moving average of $3.35 and a 200-day simple moving average of $2.91. The stock has a market capitalization of $6.38 million, a PE ratio of -1.19 and a beta of -1.18.

Alaunos Therapeutics (NASDAQ:TCRT) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.90) by $4.35.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.